Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336
Rank in Stocks
#3772
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
Share Price
$4.87
Market Cap
$4.36B
Change (1 day)
-5.47%
Change (1 year)
-15.62%
Country
CN
Trade Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Category
Healthcare
Number of shares outstanding for Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Number of shares outstanding as of October 2026: 0
According to Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of October 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336) from 2006 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2025 | 617.38M | -0.11% |
| 2024 | 618.05M | 0.70% |
| 2023 | 613.78M | -0.40% |
| 2022 | 616.22M | 2.37% |
| 2021 | 601.95M | 2.42% |
| 2020 | 587.73M | 10.22% |
| 2019 | 533.24M | 4.51% |
| 2018 | 510.22M | 0.00% |
| 2017 | 510.22M | 0.86% |
| 2016 | 505.85M | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | -100.00% |
| 2012 | 508.39M | -1.58% |
| 2011 | 516.57M | 8.92% |
| 2010 | 474.28M | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| 0.00 | - |
BE
|
|
| 62.19M | - |
NL
|
